ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Annual Meeting 2021

March 5-7, 2021  
Virtual
Registration open for on-demand viewing

ISSWSH Fall Course 2021

October 7-10, 2021   9 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

ISSWSH Annual Meeting 2022

March 3-6, 2022   159 days left
Renaissance Dallas Hotel - Dallas, TX
Visit the Meeting Website

ISSWSH Fall Course 2022

November 17-20, 2022   415 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

Latest Tweets

The ISSWSH Slide Deck is your one-stop resource on Female Sexual Function & Dysfunction. Members can purchase the s… https://t.co/KgbZa8iGf1 ISSWSH
Medical apps are becoming more popular. Do you think an app for female sexual dysfunction would be helpful? Would… https://t.co/eigxFpsM2r ISSWSH
There's still time to register for tonight's webinar on PGAD/GPD: Region 3! Registration is free for all to join:… https://t.co/4uarfi19Ey ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram